By 2035, China is projected to account for more than half of all diagnosed chronic Hepatitis C cases across eight major global pharmaceutical markets, according to a forecast by healthcare analytics firm GlobalData. With over 3.9 million diagnosed patients expected, the country’s burden highlights the long-term public health consequences of historical infection control gaps and serves as a critical case study for neighboring economies like India regarding the necessity of proactive disease surveillance.
The Legacy of Historical Health Gaps
China’s current Hepatitis C trajectory is rooted in the 1980s and 1990s, a period marked by rapid expansion in commercial plasma donation. According to health experts, unsafe blood collection practices and inadequate infection control during those decades facilitated the virus’s spread. While Beijing has since implemented more rigorous blood safety regulations and increased access to modern treatments, the “silent” nature of the disease means many individuals remain unaware of their status until liver damage—including cirrhosis or liver cancer—becomes advanced.
Did you know? Hepatitis C is often called a “silent disease” because many infected people show no symptoms for years. Modern direct-acting antiviral medicines, however, can cure more than 95 per cent of infections if caught early.
Comparative Outlook: Lessons for India
India faces different challenges but shares the risks of a large, geographically diverse population with unequal healthcare access. While India’s estimated Hepatitis C prevalence remains lower than China’s projected burden, the experience of its neighbor underscores that economic growth does not automatically resolve public health vulnerabilities.
India’s response has centered on the National Viral Hepatitis Control Programme (NVHCP), launched in 2018. The program provides free screening, diagnosis, and treatment through public health facilities. Unlike many global markets, India has successfully utilized affordable generic direct-acting antiviral drugs to expand treatment reach. However, health specialists warn that long-term success requires sustained investment in:
- Continuous disease surveillance systems.
- Public awareness campaigns in rural districts.
- Strict infection control and blood transfusion safety protocols.
Economic Growth and Healthcare Resilience
The intersection of economic performance and public health is increasingly visible in Asia. Official figures show China’s GDP grew in the second quarter of 2026, falling below Beijing’s annual target as domestic demand waned. This slowdown, coupled with the impact of the Iran war on oil prices, complicates the challenge of funding large-scale healthcare infrastructure for an aging population.
The World Health Organization (WHO) has set a target to eliminate viral hepatitis as a public health threat by 2030. Achieving this goal requires shifting focus from simple medicine availability to integrated primary healthcare. For large developing economies, this means prioritizing digital health records and laboratory capacity to reach remote communities where specialized diagnostics are often unavailable.
Pro Tip: For public health systems to succeed, they must integrate hepatitis screening into routine primary care visits rather than relying solely on specialized, standalone clinics.
Frequently Asked Questions
Why is Hepatitis C screening critical for national health?
Because the virus often causes no symptoms for years, early screening is the only way to identify infections before they cause permanent liver damage, such as cirrhosis or cancer.
What is the role of direct-acting antivirals?
These modern medications are highly effective, capable of curing more than 95 per cent of Hepatitis C infections when administered following an early diagnosis.
How does economic development affect hepatitis control?
Rapid industrialization often outpaces the development of rural healthcare infrastructure. As seen in China, even with high economic growth, historical public health shortcomings can create a long-term disease burden that requires dedicated, ongoing investment to resolve.
How is your local community addressing viral hepatitis screening? Share your thoughts or subscribe to our newsletter for more updates on regional health trends and economic policy.
Worth a look